Hearing loss

Measles is a humanitarian issue, and its unwelcome reappearance in Canada is a reminder of its importance

Retrieved on: 
Tuesday, April 9, 2024

However, new challenges, such as the disruption of health systems caused by COVID-19, have underscored the importance of measles as a public health concern.

Key Points: 
  • However, new challenges, such as the disruption of health systems caused by COVID-19, have underscored the importance of measles as a public health concern.
  • A recent surge in cases in countries such as Canada from which it had largely disappeared has helped draw new attention to this old disease.

Measles in Canada

  • Measles is one of the most infectious diseases known to science; nine out of 10 susceptible people will become infected if exposed.
  • Vaccination is such an effective tool that, in Canada, measles has been considered eliminated since 1998.
  • In short, measles is emerging as a public health problem in Canada once again.

Measles in humanitarian settings

  • In humanitarian settings like those where MSF operates, aggravated by poor living conditions and malnutrition, it can be disastrous.
  • For these reasons and more, vaccinating against measles is one of the first priorities for MSF teams in humanitarian emergencies, particularly in situations where people are forcibly displaced and living in crowded conditions like a camp.
  • In 2024, MSF is seeing record-breaking cases of measles in some of the places where our teams work, such as northeastern Nigeria.

Growing impact of vaccine-preventable diseases

  • These gaps in coverage of vaccine-preventable diseases are having significant impacts on global public health.
  • For several years, MSF has been warning of growing outbreaks of vaccine-preventable diseases in places where we work that have significant implications for people living there, but also for global public health — including impacts on countries susceptible to imported cases, such as Canada.
  • Governments and other global health funders generally understand why childhood vaccinations are important for primary health care.


Adam R Houston works for Doctors Without Borders/Médecins Sans Frontières (MSF) as the Medical Policy & Advocacy Advisor. Jason Nickerson works for Doctors Without Borders/Médecins Sans Frontières (MSF) as the Humanitarian Representative to Canada.

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Retrieved on: 
Monday, March 18, 2024

RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, United Kingdom, March 17, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.
  • It is estimated that more than 5,000 pediatric patients annually are eligible for platinum-based chemotherapy in Europe.
  • PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
  • The studies compared PEDMARQSI plus cisplatin-based regimens to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.

Sudden Hearing Loss: AudioCure's Novel Compound AC102 Restores Hearing in Preclinical Models, Published in PNAS

Retrieved on: 
Monday, April 1, 2024

A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models.

Key Points: 
  • A single application of the novel compound AC102 almost completely restores noise-induced hearing loss in preclinical models.
  • Sudden hearing loss is often treated with anti-inflammatory corticosteroids without regulatory approval or reliable evidence of effectiveness.
  • A single middle ear application of AC102 after noise trauma restores hearing to near pre-trauma levels after 14 days.
  • Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma, explains, "The HODOKORT study highlights the treatment gap for sudden hearing loss.

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

Sudden Hearing Loss: Recent Clinical Trial HODOKORT Questions Benefits of Glucocorticoid Treatment

Retrieved on: 
Tuesday, March 12, 2024

High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss.

Key Points: 
  • High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss.
  • This clinical study, led by Prof. Stefan Plontke from the University Medicine Halle, evaluated the efficacy of different doses of glucocorticoids in over 300 sudden hearing loss patients and is published in NEJM Evidence .
  • However, there is no convincing mode-of-action for the treatment of sudden hearing loss with steroids, as our own research has shown," says Dr. Reimar Schlingensiepen, CEO of AudioCure Pharma.
  • After 50 years of treating sudden hearing loss with glucocorticoids, a new and effective drug for this condition would represent a much-needed paradigm shift.

EARLENS ANNOUNCES APPOINTMENT OF ROBERT GLAZER AS STRATEGIC ADVISOR

Retrieved on: 
Monday, April 1, 2024

MENLO PARK, Calif., April 1, 2024 /PRNewswire/ -- Today, EARLENS, a leader in innovative Hearing Technology and Virtual Clinical Diagnostic Delivery Platforms, proudly announces the appointment of Robert Glazer as a Strategic Advisor to the company. Glazer, well known in the Otolaryngology, Allergy and Audiology space will play a key role in advancing the promotion of EARLENS' groundbreaking hearing solutions. 

Key Points: 
  • MENLO PARK, Calif., April 1, 2024 /PRNewswire/ -- Today, EARLENS, a leader in innovative Hearing Technology and Virtual Clinical Diagnostic Delivery Platforms, proudly announces the appointment of Robert Glazer as a Strategic Advisor to the company.
  • Glazer, well known in the Otolaryngology, Allergy and Audiology space will play a key role in advancing the promotion of EARLENS' groundbreaking hearing solutions.
  • As the company continues to push the boundaries of hearing technology and care delivery, EARLENS recognizes the value of Glazer's extensive experience.
  • "We are thrilled to welcome Robert Glazer to the EARLENS family as a strategic advisor," said J. Connon Samuel, Chief Operating Officer at EARLENS.

Chosgo K23: One of the Best Bluetooth Hearing Aids for Seniors

Retrieved on: 
Friday, March 29, 2024

ALBANY, N.Y., March 29, 2024 /PRNewswire-PRWeb/ -- The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can favor the onset of cognitive deficits of various types. People affected by hearing loss, therefore with hearing problems, have a risk twice as high as others of developing dementia.

Key Points: 
  • Hearing aids for seniors are almost a necessity and when it comes time to choose, OTC hearing aids like the Chosgo K23 offer even more advantages.
  • However, an FDA policy last October allowing the sale of OTC hearing aids without a prescription has resulted in massive price drops and less oversight of the OTC hearing aids flooding the market.
  • As a result, we recommend one product that we think is one of the best OTC hearing aids .
  • Hearing aids for seniors are almost a necessity and when it comes time to choose, OTC hearing aids like the Chosgo K23 offer even more advantages.

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Retrieved on: 
Monday, March 18, 2024

RESEARCH TRIANGLE PARK, N.C. and UXBRIDGE, England, March 18, 2024 /PRNewswire/ -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, and Norgine, a leading European specialist pharmaceutical company, today announced an exclusive licensing agreement under which Norgine will commercialize PEDMARQSI® in Europe, Australia and New Zealand. PEDMARQSI is the first and only approved therapy in the EU and U.K. for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • Norgine will be responsible for all commercialization activities in the licensed territories and will hold all marketing authorizations in the licensed territories.
  • It is estimated that more than 5,000 pediatric patients annually are eligible for platinum-based chemotherapy in Europe.
  • The studies compared PEDMARQSI plus cisplatin-based regimens to cisplatin-based regimens alone for the reduction of cisplatin-induced hearing loss in pediatric patients.
  • Moelis & Company LLC acted as financial advisor, and LaBarge Weinstein LLP acted as legal advisor to Fennec.

Sleep Specialist and Otolaryngologist, Julie Zweig, M.D., is Featured as a 2024 Top Patient Rated Doctor by Find Local Doctors

Retrieved on: 
Monday, March 11, 2024

ALPHARETTA, Ga., March 11, 2024 /PRNewswire-PRWeb/ -- Dr. Julie Zweig, a renowned, board-certified ear nose and throat (ENT) and sleep medicine physician, has been recognized as a 2024 Top Patient Rated Otolaryngologist by Find Local Doctors. This prestigious title is awarded to practices that have received an exceptional number of five-star ratings and superior reviews from satisfied patients. Find Local Doctors, a trusted online directory, is dedicated to helping consumers find reputable physicians in their area. The recognition bestowed upon Dr. Zweig and her team is a testament to their commitment to providing top-notch care and achieving outstanding patient satisfaction.

Key Points: 
  • ALPHARETTA, Ga., March 11, 2024 /PRNewswire-PRWeb/ -- Dr. Julie Zweig, a renowned, board-certified ear nose and throat (ENT) and sleep medicine physician, has been recognized as a 2024 Top Patient Rated Otolaryngologist by Find Local Doctors.
  • Find Local Doctors , a trusted online directory, is dedicated to helping consumers find reputable physicians in their area.
  • Julie Zweig, MD Integrative Sleep & ENT is located at 2650 Holcomb Bridge Road, Suite 510 in Alpharetta, Georgia.
  • Dr. Julie Zweig, Julie Zweig, MD Integrative Sleep & ENT, 404-255-4080, [email protected] , https://juliezweigmd.com/
    View original content to download multimedia: https://www.prweb.com/releases/sleep-specialist-and-otolaryngologist-jul...